Challenging Times for European Biotech IPOs
This article was originally published in Start Up
Executive Summary
Through the first week of May, 2005, five biotechs listed on Europe's main markets. Like their counterparts in the US, these companies have had to deal with difficult public markets and have on the whole raised much less money than they originally intended.
You may also be interested in...
Reverse Mergers Gain Traction In Tough IPO Times
Reverse mergers like Micromet's takeover of Cancervax and Cyclacel's takeover of Xcyte Therapies illustrate both tough times for IPO contenders as well as the innovative and sometimes win-win solution a reverse merger can provide.
Reverse Mergers Gain Traction In Tough IPO Times
Reverse mergers like Micromet's takeover of Cancervax and Cyclacel's takeover of Xcyte Therapies illustrate both tough times for IPO contenders as well as the innovative and sometimes win-win solution a reverse merger can provide.
Stepping Out, Not Up: Better Returns for VCs Through M&A?
IPOs are no longer a liquidity event for venture investors, who are increasingly turning to M&A to help balance portfolio returns.